Table 1.
Baseline characteristics of patients with five‐dimension European quality of life questionnaire measurements
| Liraglutide N = 1506 | Placebo N = 1508 | |
|---|---|---|
| Age, years | 65.3 (7.3) | 65.9 (7.0) |
| BMIa, kg/m2 | 33.4 (6.3) | 33.1 (5.9) |
| Weight, kg | 97.2 (20.5) | 95.7 (19.1) |
| HbA1c, mmol/mol | 68 (15) | 68 (14) |
| Duration of diabetesa, years | 12.5 (7.7) | 12.7 (8.2) |
| Insulin‐naive, n (%) | 620 (41.2) | 645 (42.8) |
| Years of observationb, years | 3.9 (0.6) | 3.9 (0.7) |
| EQ‐5D index score | 0.79 (0.24) | 0.78 (0.24) |
| EQ‐5D VAS score | 74.7 (17.2) | 74.3 (17.9) |
Abbreviations: BMI, body mass index; EQ‐5D, five‐dimension European Quality of Life questionnaire; HbA1c, glycated haemoglobin; N, number of patients with EQ‐5D measurements; VAS, visual analogue scale.
Full analysis set. Data are mean (standard deviation, SD) unless otherwise stated.
a
BMI data only available for 1505 and 1506 patients in the liraglutide and placebo treatment groups, respectively; duration of diabetes data only available for 1505 and 1503 patients, respectively.
b
Including follow‐up years.